MannKind competitors

Robert Kramer is a President & Chief Executive Officer at EMERGENT BIOSOLUTIONS INC., Board Member at EMERGENT BIOSOLUTIONS INC., and Interim Exec VP:Services at EMERGENT BIOSOLUTIONS INC. and is based in Lansing, Michigan. He has experience at PHARMACIA CORP and has worked as Pres:Biosciences Div at EMERGENT BIOSOLUTIONS INC., Consultant at EMERGENT BIOSOLUTIONS INC., and President at Emergent Biodefense Ops Lansg. Robert works or has worked as Chief Executive Officer at Emergent Biodefense Operations. He studied at WESTERN KENTUCKY UNIVERSITY between 1980 and 1983 and Clemson University between 1975 and 1979.

Executive Officer with over 20 years of transactional and operational experience in venture capital backed startups to mature fully integrated organizations in the biotechnology, medical device, and pharmaceutical industries. Completed strategic transactions & shareholder exits totaling |$530M, venture capital/royalty fundraising totaling |$70M, and public offerings (IPO and secondary) totaling |$200M. Established strategy as part of executive management teams, growing revenues to |$300M, hired and led senior (C-Level to VP level) leadership teams, and secured multiple FDA PMA, NDA, and 510(k) approvals. Functional leadership in and P&L responsibility for market development, international sales distribution, M&A/business development, R&D, regulatory & clinical affairs, manufacturing & logistics, patent & legal affairs, quality operations, facilities, finance, and information technology.Areas of expertise include: Organization Transformation, R&D, Strategic Planning, Integrating Acquisitions and Products, Business Development, Investor & Shareholder Relations, Board of Directors and KOL Engagement, Crisis Management & Restructuring, Product Development, FDA & Global Regulatory Approvals, Lean & Continuous Improvement, Financial Analysis, and P&L/Cost Management.

Francis Aurelio deSouza (born December 2, 1970) is an American entrepreneur and business executive. He is the president and chief executive officer (CEO) of Illumina and a member of the Board of Directors of The Walt Disney Company.

Richard Maradie is a Chief Executive Officer at NOVAVAX INC and is based in Rockville, Maryland.

CEO at T2 Biosystems | Board Member | Heart Transplant Recipient | Sepsis Survivor | Best Selling Author | Inspirational Speaker

Vijay Samant is a Board Member at Brickell Biotech Inc. He has worked as President/CEO at Vical; Trustee at International Vaccine Institute (IVI); and VP:Vaccine/Exec Dir:Materials Mgmt at MERCK & CO., INC.. Vijay studied at Columbia University, University of Mumbai, and MIT Sloan.

Chief Executive Officer and member of the board of XOMA (NASDAQ: XOMA). Joined XOMA in 2009 and was appointed to the CEO role in late 2016. In early 2017, Mr. Neal led XOMA through a dramatic strategic pivot taking the company from a traditional R&D heavy biotech company and transforming it to a successful royalty monetization and aggregation company. In the years prior to becoming CEO of XOMA, he was instrumental in leading the company’s licensing and business development activities focused on maximizing the value of XOMA’s foundational antibody IP and knowhow. In addition to his role at XOMA, Mr. Neal currently serves as a Director at Leading Biosciences, a clinical stage biotech company based in Carlsbad, CA. Mr. Neal has more than twenty years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Prior to XOMA, Mr. Neal was Acting Chief Executive Officer of Entelos Inc., a leading bio-simulation company that acquired Iconix Biosciences, a privately held company where Mr. Neal was Chief Executive Officer. At Iconix, Mr. Neal established multi-year collaborations with Bristol-Myers Squibb, Abbott Labs (now AbbVie), Eli Lilly and the U.S. Food and Drug Administration. From 1999-2002, he was Executive Vice President of Incyte Genomics, leading global commercial activities with pharmaceutical company collaborators and partners including Pfizer, Aventis, GSK and others. Earlier in his career, he was an executive with Monsanto Company in positions of increasing responsibility. Mr. Neal earned his B.S. in Biology and his M.S. in Genetics and Plant Breeding from the University of Manitoba, Canada, and holds an MBA degree from Washington University in St. Louis, MO.

Jean-Claude Dubacher is Chairman and CEO of B. Braun of America Inc., which includes B. Braun Medical Inc., B. Braun Interventional Systems, Aesculap® and CAPS®. Mr. Dubacher joined B. Braun in August 2019 as President, B. Braun Medical Inc., and has served as Chairman and Chief Executive Officer of B. Braun Medical Inc. since January 1, 2020. Dubacher’s experience in healthcare spans more than 15 years in consulting and corporate roles including strategy, commercial, supply chain and manufacturing. Prior to joining B. Braun, Dubacher led commercial operations for the Surgical Ophthalmology Division of Johnson & Johnson (formerly Abbott Medical Optics) in Europe. Throughout his career, Mr. Dubacher has demonstrated a passion for focusing on customer needs and supporting people to be successful in developing, manufacturing, marketing, and selling products and services that benefit patients. Dubacher holds a Doctorate Degree in law (Dr. iur.) from the University of Zurich in Switzerland, and an MBA from Harvard Business School. He is a board member for the German American Chamber of Commerce.

Alexander Hardy is the CEO of Genentech. Hardy, who joined Genentech in 2005, has served as CEO since March 1, 2019. He previously served as head of global product Strategy for Roche Pharmaceuticals. Previously, he headed up Asia Pacific for Roche's pharma outfit.